21st Apr 2022 06:01
(Alliance News) - AstraZeneca PLC late Wednesday said a clinical trial found its Evusheld antibody therapy markedly reduced the risk of developing symptomatic Covid-19.
The drugmaker added that in a six-month follow-up of the Provent phase III trial, there were no severe Covid-19 cases of deaths.
"While Covid-19 vaccines have been highly effective at reducing hospitalisation and death, cases continue to surge and many individuals remain at high risk, including immunocompromised individuals and those who cannot be vaccinated," Myron Levin, a trial investigator, explained.
The company said Evusheld reduced the risk of developing symptomatic Covid-19 by 77% in primary analysis and by 83% in the six-month follow-up analysis, compared to a placebo.
AstraZeneca added: "More than 75% of Provent participants at baseline had co-morbidities that put them at high risk for severe Covid-19 if they were to become infected, including people who are immunocompromised and may have an inadequate immune response to vaccination.
"Additional pharmacokinetic data showed that Evusheld concentrations remained elevated in serum for six months after administration, supporting that a single dose could provide long-term protection against Covid-19 lasting at least six months."
By Eric Cunha; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca